Product Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

CAS:876343-10-1
Molecular Formula:C6H3ClIN3
Purity:95%+
Catalog Number:CM104043
Molecular Weight:279.47

Packing Unit Available Stock Price($) Quantity
CM104043-5g in stock ůʼnŹ
CM104043-10g in stock ƓưǤ
CM104043-25g in stock ʼnưŹ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:876343-10-1
Molecular Formula:C6H3ClIN3
Melting Point:-
Smiles Code:ClC1=C2C=C(I)NC2=NC=N1
Density:
Catalog Number:CM104043
Molecular Weight:279.47
Boiling Point:
MDL No:MFCD11518919
Storage:-20°C

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

BMF-219
Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.

Related Products